## PD-L1 High: ICI Monotherapy by HIC

## mOS in months (95% CI) — HIC-H, n = 53 NR (9.5-und) -- · HIC-C, n = 30 2.6 (1.6-6.3) HR (95% CI): 0.34 (0.19-0.61), p = <0.001 100 **OVERALL SURVIVAL (%)** 12 15 18 3 TIME (MONTHS) No. at Risk: HIC-H 53 44 17

37

10

30

HIC-C

12

## PD-L1 High: ICI + Chemotherapy by HIC




Figure S3. Kaplan-Meier analysis of overall survival in patients with advanced stage NSCLC, PD-L1 expression ≥50% receiving an ICI containing regimen in first-line setting by HIC classification, therapy type and multivariate analysis. CI, confidence interval; HIC-H, HIC-Hot; HIC-C, HIC-Cold; HR, hazard ratio; mOS, median overall survival; NR, not reached; PS, ECOG performance status; und, undefined.

5

25

7

7




Figure S4. Kaplan-Meier analysis of overall survival in patients with advanced stage NSCLC, PS 0-1, and PD-L1 expression ≥50% receiving an ICI containing regimen in first-line setting by HIC, therapy type. CI, confidence interval; HIC-H, HIC-Hot; HIC-C, HIC-Cold; HR, hazard ratio; mOS, median overall survival; NR, not reached; PS, ECOG performance status; und, undefined.